Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

HCM

HUTCHMED China (HCM)

HUTCHMED China Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HCM
DateTimeSourceHeadlineSymbolCompany
26/04/202422:30GlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNASDAQ:HCMHUTCHMED China Limited
05/04/202419:30GlobeNewswire Inc.HUTCHMED Highlights Data to be Presented at AACR Congress 2024NASDAQ:HCMHUTCHMED China Limited
02/04/202415:30GlobeNewswire Inc.HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
28/03/202411:00GlobeNewswire Inc.HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCNASDAQ:HCMHUTCHMED China Limited
22/03/202411:00GlobeNewswire Inc.HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaNASDAQ:HCMHUTCHMED China Limited
05/03/202422:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
28/02/202422:47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
28/02/202422:40Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:HCMHUTCHMED China Limited
28/02/202422:30GlobeNewswire Inc.HUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
07/02/202422:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
07/02/202411:00GlobeNewswire Inc.HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series SessionNASDAQ:HCMHUTCHMED China Limited
02/02/202422:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
02/02/202419:30GlobeNewswire Inc.HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipNASDAQ:HCMHUTCHMED China Limited
01/02/202422:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
01/02/202419:30GlobeNewswire Inc.HUTCHMED to Announce 2023 Final ResultsNASDAQ:HCMHUTCHMED China Limited
30/01/202422:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
30/01/202415:53GlobeNewswire Inc.HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
11/01/202422:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
11/01/202411:00GlobeNewswire Inc.HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
29/12/202322:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
21/12/202322:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
13/12/202322:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
13/12/202315:30GlobeNewswire Inc.HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current TermsNASDAQ:HCMHUTCHMED China Limited
13/12/202311:00GlobeNewswire Inc.HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in ChinaNASDAQ:HCMHUTCHMED China Limited
07/12/202322:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
01/12/202322:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
01/12/202311:00GlobeNewswire Inc.HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology CongressesNASDAQ:HCMHUTCHMED China Limited
30/11/202322:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
11/11/202300:35GlobeNewswire Inc.Deutsche Bank ADR Investor Conference: Presentations Now Available for Online ViewingNASDAQ:HCMHUTCHMED China Limited
09/11/202322:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
 Showing the most relevant articles for your search:NASDAQ:HCM